A citation-based method for searching scientific literature

Hui Shi, Le-Hang Guo, Yi-Feng Zhang, Hui-Jun Fu, Jia-Yi Zheng, Han-Xiang Wang, Chong-Ke Zhao, Hui-Xiong Xu. Endocrine 2020
Times Cited: 2







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.
Mingzhao Xing, Rengyun Liu, Xiaoli Liu, Avaniyapuram Kannan Murugan, Guangwu Zhu, Martha A Zeiger, Sara Pai, Justin Bishop. J Clin Oncol 2014
390
100


Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Young Shin Song, Jung Ah Lim, Hoonsung Choi, Jae-Kyung Won, Jae Hoon Moon, Sun Wook Cho, Kyu Eun Lee, Young Joo Park, Ka Hee Yi, Do Joon Park,[...]. Cancer 2016
91
50



GABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer.
Yanxia Guo, Xiaotian Yuan, Kailin Li, Mingkai Dai, Lu Zhang, Yujiao Wu, Chao Sun, Yuan Chen, Guanghui Cheng, Cheng Liu,[...]. Cell Death Differ 2020
14
50

Ultrasonographic prediction of highly aggressive telomerase reverse transcriptase (TERT) promoter-mutated papillary thyroid cancer.
Tae Hyuk Kim, Chang-Seok Ki, Soo Yeon Hahn, Young Lyun Oh, Hye Won Jang, Sun Wook Kim, Jae Hoon Chung, Jung Hee Shin. Endocrine 2017
7
50

In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation.
Almira Nasirden, Tsuyoshi Saito, Yuki Fukumura, Kieko Hara, Keisuke Akaike, Aiko Kurisaki-Arakawa, Miki Asahina, Atsushi Yamashita, Ran Tomomasa, Takuo Hayashi,[...]. Virchows Arch 2016
27
50

TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel.
Jie Tan, Rengyun Liu, Guangwu Zhu, Christopher B Umbricht, Mingzhao Xing. Proc Natl Acad Sci U S A 2020
10
50

Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis.
Haoyu Ren, Yifan Shen, Daixing Hu, Wei He, Jing Zhou, Yijia Cao, Yu Mao, Yi Dou, Wei Xiong, Qi Xiao,[...]. Cancer Manag Res 2018
20
50

PLEKHS1 Over-Expression is Associated with Metastases and Poor Outcomes in Papillary Thyroid Carcinoma.
Xiangling Xing, Ninni Mu, Xiaotian Yuan, Na Wang, C Christofer Juhlin, Klas Strååt, Catharina Larsson, Dawei Xu. Cancers (Basel) 2020
8
50

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.
Jian Sun, Jing Zhang, Junliang Lu, Jie Gao, Xinyu Ren, Lianghong Teng, Huanli Duan, Yansong Lin, Xiaoyi Li, Bo Zhang,[...]. PLoS One 2016
30
50

Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis.
Gabriela M Baerlocher, Bart Burington, David S Snyder. N Engl J Med 2015
7
50

TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Na Wang, Tiantian Liu, Anastasios Sofiadis, C Christofer Juhlin, Jan Zedenius, Anders Höög, Catharina Larsson, Dawei Xu. Cancer 2014
74
50

Telomere attrition predominantly occurs in precursor lesions during in vivo carcinogenic process of the uterine cervix.
Anju Zhang, Jianliu Wang, Biying Zheng, Xiaolei Fang, Tord Angström, Cheng Liu, Xidan Li, Fredrik Erlandsson, Magnus Björkholm, Magnus Nordenskjörd,[...]. Oncogene 2004
40
50

Clinical Routine TERT Promoter Mutational Screening of Follicular Thyroid Tumors of Uncertain Malignant Potential (FT-UMPs): A Useful Predictor of Metastatic Disease.
Martin Hysek, Johan O Paulsson, Kenbugul Jatta, Ivan Shabo, Adam Stenman, Anders Höög, Catharina Larsson, Jan Zedenius, Carl Christofer Juhlin. Cancers (Basel) 2019
18
50

The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.
Xiaotian Yuan, Guanghui Cheng, Jingya Yu, Shunzhen Zheng, Chao Sun, Qing Sun, Kailin Li, Zhaomin Lin, Tiantian Liu, Ping Li,[...]. Oncotarget 2017
21
50


Telomere-related Markers for Cancer.
Xiaotian Yuan, Mingkai Dai, Dawei Xu. Curr Top Med Chem 2020
14
50

TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer.
Xue Yang, Jiao Li, Xiaoyi Li, Zhiyong Liang, Wen Gao, Jun Liang, Shujun Cheng, Yansong Lin. J Nucl Med 2017
43
50

TERTp mutation is associated with a shorter progression free survival in patients with aggressive histology subtypes of follicular-cell derived thyroid carcinoma.
Gustavo C Penna, Ana Pestana, José Manuel Cameselle, Denise Momesso, Fernanda Accioly de Andrade, Ana Paula Aguiar Vidal, Mario Lucio Araujo Junior, Miguel Melo, Priscila Valverde Fernandes, Rossana Corbo,[...]. Endocrine 2018
10
50

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers.
Iñigo Landa, Tihana Ibrahimpasic, Laura Boucai, Rileen Sinha, Jeffrey A Knauf, Ronak H Shah, Snjezana Dogan, Julio C Ricarte-Filho, Gnana P Krishnamoorthy, Bin Xu,[...]. J Clin Invest 2016
478
50

Highly prevalent TERT promoter mutations in aggressive thyroid cancers.
Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar, Mingzhao Xing. Endocr Relat Cancer 2013
370
50

Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers.
Josh Lewis Stern, Dan Theodorescu, Bert Vogelstein, Nickolas Papadopoulos, Thomas R Cech. Genes Dev 2015
108
50

Evidence of oncogene-induced senescence in thyroid carcinogenesis.
Maria Grazia Vizioli, Patricia A Possik, Eva Tarantino, Katrin Meissl, Maria Grazia Borrello, Claudia Miranda, Maria Chiara Anania, Sonia Pagliardini, Ettore Seregni, Marco A Pierotti,[...]. Endocr Relat Cancer 2011
34
50

MYC-dependent downregulation of telomerase by FLT3 inhibitors is required for their therapeutic efficacy on acute myeloid leukemia.
Xiaolu Zhang, Bingnan Li, Jingya Yu, Jenny Dahlström, Anh Nhi Tran, Magnus Björkholm, Dawei Xu. Ann Hematol 2018
14
50

Prognostic Significance of TERT Promoter Mutations in Papillary Thyroid Carcinomas in a BRAF(V600E) Mutation-Prevalent Population.
Seung Eun Lee, Tae Sook Hwang, Yoon-La Choi, Hye Seung Han, Wan Seop Kim, Min Hye Jang, Suk Kyeong Kim, Jung Hyun Yang. Thyroid 2016
42
50

Deep neural networks could differentiate Bethesda class III versus class IV/V/VI.
Yi Zhu, Qiang Sang, Shijun Jia, Ying Wang, Timothy Deyer. Ann Transl Med 2019
7
50

WNT/β-Catenin Directs Self-Renewal Symmetric Cell Division of hTERThigh Prostate Cancer Stem Cells.
Kai Zhang, Yanjing Guo, Xue Wang, Huifang Zhao, Zhongzhong Ji, Chaping Cheng, Li Li, Yuxiang Fang, Dawei Xu, Helen He Zhu,[...]. Cancer Res 2017
76
50

Preoperative Assessment of TERT Promoter Mutation on Thyroid Core Needle Biopsies Supports Diagnosis of Malignancy and Addresses Surgical Strategy.
A Crescenzi, P Trimboli, D C Modica, C Taffon, L Guidobaldi, S Taccogna, A Rainer, M Trombetta, E Papini, G Zelano. Horm Metab Res 2016
23
50

Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension.
Megan R Haymart, Simone L Glinberg, Jing Liu, Rebecca S Sippel, Juan C Jaume, Herbert Chen. Clin Endocrinol (Oxf) 2009
76
50

Telomerase reverse transcriptase regulates DNMT3B expression/aberrant DNA methylation phenotype and AKT activation in hepatocellular carcinoma.
Jingya Yu, Xiaotian Yuan, Louise Sjöholm, Tiantian Liu, Feng Kong, Tomas J Ekström, Magnus Björkholm, Dawei Xu. Cancer Lett 2018
24
50


JAK2 inhibition in JAK2V617F-bearing leukemia cells enriches CD34+ leukemic stem cells that are abolished by the telomerase inhibitor GRN163L.
Jenny Dahlström, Chuanyou Xia, Xiangling Xing, Xiaotian Yuan, Magnus Björkholm, Dawei Xu. Biochem Biophys Res Commun 2020
5
50

GABPA inhibits invasion/metastasis in papillary thyroid carcinoma by regulating DICER1 expression.
Xiaotian Yuan, Ninni Mu, Na Wang, Klas Strååt, Anastasios Sofiadis, Yanxia Guo, Adam Stenman, Kailin Li, Guanghui Cheng, Lu Zhang,[...]. Oncogene 2019
22
50

Telomerase and Telomeres Biology in Thyroid Cancer.
Benedetta Donati, Alessia Ciarrocchi. Int J Mol Sci 2019
10
50

Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.
Aime T Franco, Roberta Malaguarnera, Samuel Refetoff, Xiao-Hui Liao, Emma Lundsmith, Shioko Kimura, Catrin Pritchard, Richard Marais, Terry F Davies, Lee S Weinstein,[...]. Proc Natl Acad Sci U S A 2011
140
50

Rising Incidence and Incidence-Based Mortality of Thyroid Cancer in California, 2000-2017.
Kimberly L Yan, Shanpeng Li, Chi-Hong Tseng, Jiyoon Kim, Dalena T Nguyen, Nardeen B Dawood, Masha J Livhits, Michael W Yeh, Angela M Leung. J Clin Endocrinol Metab 2020
20
50

Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.
Robert J A Bell, H Tomas Rube, Alex Kreig, Andrew Mancini, Shaun D Fouse, Raman P Nagarajan, Serah Choi, Chibo Hong, Daniel He, Melike Pekmezci,[...]. Science 2015
300
50


Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.
Rengyun Liu, Tao Zhang, Guangwu Zhu, Mingzhao Xing. Nat Commun 2018
83
50


Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations.
Soo Yeon Hahn, Tae Hyuk Kim, Chang Seok Ki, Sun Wook Kim, Soohyun Ahn, Jung Hee Shin, Jae Hoon Chung. Oncotarget 2017
11
50

Functions of stem cells of thyroid glands in health and disease.
Ebtesam A Al-Suhaimi, Khulood Al-Khater. Rev Endocr Metab Disord 2019
4
50

The Current Histologic Classification of Thyroid Cancer.
Sylvia L Asa. Endocrinol Metab Clin North Am 2019
24
50

TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR.
Kun Wang, Tiantian Liu, Nan Ge, Li Liu, Xiaotian Yuan, Jikai Liu, Feng Kong, Chang Wang, Hongbo Ren, Keqiang Yan,[...]. Oncotarget 2014
41
50

Somatic mutations in telomerase promoter counterbalance germline loss-of-function mutations.
Lindley Maryoung, Yangbo Yue, Ashley Young, Chad A Newton, Cindy Barba, Nicolai S C van Oers, Richard C Wang, Christine Kim Garcia. J Clin Invest 2017
30
50

TERT promoter mutations in familial and sporadic melanoma.
Susanne Horn, Adina Figl, P Sivaramakrishna Rachakonda, Christine Fischer, Antje Sucker, Andreas Gast, Stephanie Kadel, Iris Moll, Eduardo Nagore, Kari Hemminki,[...]. Science 2013
50

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
Iñigo Landa, Ian Ganly, Timothy A Chan, Norisato Mitsutake, Michiko Matsuse, Tihana Ibrahimpasic, Ronald A Ghossein, James A Fagin. J Clin Endocrinol Metab 2013
263
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.